Victor Galan-Gomez
Overview
Explore the profile of Victor Galan-Gomez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
15
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molinos-Quintana A, Martinez-Cibrian N, Alonso-Saladrigues A, Galan-Gomez V, Bailen R, Buendia-Lopez S, et al.
Bone Marrow Transplant
. 2024 Nov;
60(2):250-253.
PMID: 39551836
No abstract available.
2.
Velasco Puyo P, Tagarro A, Garcia-Obregon S, Villate O, Moraleda C, Huerta Aragones J, et al.
Pediatr Blood Cancer
. 2024 Jun;
71(8):e31120.
PMID: 38825724
The EPICO (Spanish general registry of COVID-19 in children)-SEHOP (Spanish Society of Pediatric Hematology and Oncology) platform gathers data from children with SARS-CoV-2 in Spain, allowing comparison between children with...
3.
Echecopar C, Del Val Rey I, Galan-Gomez V, Gonzalez-Perez C, Mozo Del Castillo Y, Gonzalez Martinez B, et al.
An Pediatr (Engl Ed)
. 2024 Mar;
100(4):259-267.
PMID: 38548564
Introduction: Total body irradiation (TBI) is part of the myeloablative conditioning for hematopoietic stem cell transplantation (HSCT) in malignant hematologic disorders. This therapy has recently shown improved survival in acute...
4.
Molinos-Quintana A, Alonso-Saladrigues A, Herrero B, Caballero-Velazquez T, Galan-Gomez V, Panesso M, et al.
Front Immunol
. 2024 Feb;
15:1373852.
PMID: 38384474
[This corrects the article DOI: 10.3389/fimmu.2023.1280580.].
5.
Echecopar C, Abad I, Galan-Gomez V, Mozo Del Castillo Y, Sisinni L, Bueno D, et al.
Eur J Haematol
. 2024 Feb;
112(6):910-916.
PMID: 38333914
Background: Hematopoietic stem cell transplantation (HSCT) is a procedure with high morbidity and mortality. Identifying patients for maximum benefit and risk assessment is crucial in the decision-making process. This has...
6.
Molinos-Quintana A, Alonso-Saladrigues A, Herrero B, Caballero-Velazquez T, Galan-Gomez V, Panesso M, et al.
Front Immunol
. 2024 Jan;
14:1280580.
PMID: 38292483
Introduction: Loss of B-cell aplasia (BCA) is a well-known marker of functional loss of CD19 CAR-T. Most relapses and loss of BCA occur in the first months after CD19 CAR-T...
7.
Ochoa-Fernandez B, Galan-Gomez V, Guerra-Garcia P, Sanroman S, Martinez I, Bueno D, et al.
Front Pediatr
. 2023 Jun;
11:1166176.
PMID: 37325355
Objectives: This study aimed to evaluate the characteristics and outcomes of infant patients with leukemia. Methods: A retrospective analysis was conducted in a cohort of 39 patients diagnosed with infant...
8.
Casado-Lopez E, Rey-Garcia J, Galan-Gomez V, Pozo-Kreillinger J, Perez-Martinez A
An Pediatr (Engl Ed)
. 2022 Oct;
97(5):352-354.
PMID: 36192351
No abstract available.
9.
Martinez-Romera I, Galan-Gomez V, Gonzalez-Martinez B, Guerra Garcia P, San Roman Pacheco S, Corral Sanchez D, et al.
Front Immunol
. 2022 Aug;
13:960412.
PMID: 36003375
Treatment targeting CD19 by a chimeric antigen receptor expressed on T cells (anti-CD19 CAR-T) has led to a breakthrough in the management and treatment of relapsed and refractory B- cell...
10.
Gutierrez-Jimeno M, Panizo-Morgado E, Calvo-Imirizaldu M, Galan-Gomez V, Escudero-Lopez A, Patino-Garcia A
Front Pediatr
. 2022 Jul;
10:875510.
PMID: 35844738
We report the case of a 7-month-old female patient who developed acute megakaryoblastic leukemia 6 months after the appearance of skull bone lesions. Initial evaluation and diagnosis of this patient...